Literature DB >> 22041864

Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.

M-S M Ardawi1, A M Al-Sibiany, T M Bakhsh, A A Rouzi, M H Qari.   

Abstract

UNLABELLED: Decreased serum sclerostin was evident in patients with primary hyperparathyroidism and was inversely related to parathyroid hormone (PTH). Sclerostin normalized earlier than biochemical bone turnover markers (BTMs) following parathyroidectomy.
INTRODUCTION: There is limited information on the changes of serum sclerostin in conditions with chronic PTH excess in humans. The main objectives of the present study were to: (1) examine cross-sectionally the changes of serum sclerostin levels in patients with primary hyperparathyroidism (PHPT), (2) study the time course changes in serum sclerostin in PHPT patients following parathyroidectomy (PTX) followed up longitudinally for 12 months, and (3) compare the changes in serum sclerostin to that of BTMs.
METHODS: We studied 60 PHPT patients and compared them with 74 PTX patients together with 268 age- and sex-matched healthy controls. Also, we followed 27 PTX patients longitudinally at 2, 4, 6, 10, 30, 60, 180, and 360 days postoperatively. Serum sclerostin, BTMs, and minerals were measured. Also, bone mineral density was determined by dual energy X-ray absorptiometry.
RESULTS: Patients with PHPT exhibited significantly lower mean serum sclerostin [mean, in picomoles per liter; 95% confidence interval (CI)] (28.98; 27.94-30.03) than that obtained for PTX patients (37.01; 35.75-38.27) and healthy controls (46.22; 45.13-47.31) (P < 0.0001, for each case), respectively. Serum PTH inversely correlated with serum sclerostin (r = -0.651, P < 0.0001). Serum sclerostin was normalized in PTX patients by the tenth day postoperatively and remained within the expected reference range thereafter.
CONCLUSIONS: Significantly decreased serum sclerostin was evidenced in PHPT patients as compared with PTX and euparathyroid controls. The inverse PTH and sclerostin relationship suggests that sclerostin is downregulated by PTH in humans. Serum sclerostin normalized earlier than BTMs following parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041864     DOI: 10.1007/s00198-011-1806-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

1.  Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy.

Authors:  P Christiansen; T Steiniche; K Brixen; I Hessov; F Melsen; L Heickendorff; L Mosekilde
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

2.  Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.

Authors:  Michael S Ominsky; Fay Vlasseros; Jacquelin Jolette; Susan Y Smith; Brian Stouch; George Doellgast; Jianhua Gong; Yongming Gao; Jin Cao; Kevin Graham; Barbara Tipton; Jill Cai; Rohini Deshpande; Lei Zhou; Michael D Hale; Daniel J Lightwood; Alistair J Henry; Andrew G Popplewell; Adrian R Moore; Martyn K Robinson; David L Lacey; W Scott Simonet; Chris Paszty
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

3.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.

Authors:  J Pfeilschifter; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

5.  Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.

Authors:  Melissa McNulty; Ravinder J Singh; Xujian Li; Eric J Bergstralh; Rajiv Kumar
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

6.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

7.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

8.  Effects of parathyroidectomy on lead mobilization from bone in patients with primary hyperparathyroidism.

Authors:  W Osterode; R Winker; C Bieglmayer; H Vierhapper
Journal:  Bone       Date:  2004-10       Impact factor: 4.398

9.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  22 in total

1.  Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.

Authors:  Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra
Journal:  Bone       Date:  2012-06-15       Impact factor: 4.398

Review 2.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

3.  Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.

Authors:  P D'Amelio; F Sassi; I Buondonno; G Fornelli; E Spertino; L D'Amico; M Marchetti; M Lucchiari; I Roato; G C Isaia
Journal:  Osteoporos Int       Date:  2015-06-12       Impact factor: 4.507

Review 4.  Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation.

Authors:  Yurong Fei; Marja M Hurley
Journal:  J Cell Physiol       Date:  2012-11       Impact factor: 6.384

Review 5.  Bone turnover in hyperparathyroidism.

Authors:  Katharina Kerschan-Schindl
Journal:  Wien Med Wochenschr       Date:  2012-07-18

Review 6.  Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Curr Opin Pharmacol       Date:  2015-04-05       Impact factor: 5.547

Review 7.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

Review 8.  Clinical utility of serum sclerostin measurements.

Authors:  Bart L Clarke; Matthew T Drake
Journal:  Bonekey Rep       Date:  2013-06-05

9.  Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels.

Authors:  Sandra Jastrzebski; Judith Kalinowski; Marina Stolina; Faryal Mirza; Elena Torreggiani; Ivo Kalajzic; Hee Yeon Won; Sun-Kyeong Lee; Joseph Lorenzo
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

Review 10.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.